Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 10;615(7953):687–696. doi: 10.1038/s41586-022-05531-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a, Consolidated standards of reporting trials diagram, with the number of patients who provided consent, continued onto TCR isolation and leukapheresis, had clinical products manufactured for them, were infused with neoTCR transgenic T cells and provided blood and biopsy samples for analyses. DLT, dose-limiting toxicity. b, Expansion and persistence of neoTCR transgenic T cells in peripheral blood of patients, as measured by flow cytometry of stained peptide–HLA multimer cells. Percentages of total T cells from patients in the dose level 1 (DL1), DL2 and DL3 groups are shown. Patients who also received IL-2 therapy are indicated by dotted lines. All available time points were analysed. For patient 0613, 1.3% neoTCR⁺ cells was measured at day 106 after infusion. The limit of detection is approximately 0.16%.